Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (191-200 of 225) with videos related to

Pageof 23
Sort By:
Journal of Thrombosis and Haemostasis : JTH|December 11, 2020
Clinical history of cancer-associated splanchnic vein thrombosisEmanuele Valeriani, Marcello Di Nisio, Nicoletta Riva, et al.
Blood Advances|May 25, 2022
Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysisMatteo Candeloro, Emanuele Valeriani, Manuel Monreal, et al.
Circulation|November 15, 2013
Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolismNils Kucher, Peter Boekstegers, Oliver J Müller, et al.
Circulation|February 21, 2023
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa InhibitorsTruman J Milling, Saskia Middeldorp, Lizhen Xu, et al.
Thrombosis and Haemostasis|May 22, 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE studyJeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
European Journal of Internal Medicine|January 21, 2020
Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapyLaura Franco, Maurizio Paciaroni, Maria Lotti Enrico, et al.
Thrombosis and Haemostasis|August 19, 2016
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studiesMarcello Di Nisio, Maria C Vedovati, Antoni Riera-Mestre, et al.
Thrombosis Research|August 2, 2018
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirinPaolo Prandoni, Anthonie W A Lensing, Martin H Prins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort StudyNoémie Kraaijpoel, Suzanne M Bleker, Guy Meyer, et al.
Blood Advances|November 29, 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patientsHolger J Schünemann, Mary Cushman, Allison E Burnett, et al.
Pageof 23

Showing results (191-200 of 225) with videos related to

Sort By:
Pageof 23
Journal of Thrombosis and Haemostasis : JTH|December 11, 2020
Clinical history of cancer-associated splanchnic vein thrombosisEmanuele Valeriani, Marcello Di Nisio, Nicoletta Riva, et al.
Blood Advances|May 25, 2022
Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysisMatteo Candeloro, Emanuele Valeriani, Manuel Monreal, et al.
Circulation|November 15, 2013
Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolismNils Kucher, Peter Boekstegers, Oliver J Müller, et al.
Circulation|February 21, 2023
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa InhibitorsTruman J Milling, Saskia Middeldorp, Lizhen Xu, et al.
Thrombosis and Haemostasis|May 22, 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE studyJeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, et al.
European Journal of Internal Medicine|January 21, 2020
Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapyLaura Franco, Maurizio Paciaroni, Maria Lotti Enrico, et al.
Thrombosis and Haemostasis|August 19, 2016
Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studiesMarcello Di Nisio, Maria C Vedovati, Antoni Riera-Mestre, et al.
Thrombosis Research|August 2, 2018
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirinPaolo Prandoni, Anthonie W A Lensing, Martin H Prins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2019
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort StudyNoémie Kraaijpoel, Suzanne M Bleker, Guy Meyer, et al.
Blood Advances|November 29, 2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patientsHolger J Schünemann, Mary Cushman, Allison E Burnett, et al.
Pageof 23